Trial Profile
International, Multicenter, Open-label, Phase II Study to Investigate the Efficacy and Safety of Multiple Doses of IMAB362 in Patients With Advanced Adenocarcinoma of the Stomach or the Lower Esophagus
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 23 Dec 2021
Price :
$35
*
At a glance
- Drugs Zolbetuximab (Primary)
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
- Acronyms MONO
- Sponsors Ganymed Pharmaceuticals
- 26 Jun 2019 Czech Republic, Poland and Turkey were planned locations as per European Clinical Trials Database.
- 26 Jun 2019 Results published in the Annals of Oncology
- 17 Dec 2015 Status changed from active, no longer recruiting to completed.